CLINICAL TRIALS PROFILE FOR LESCOL XL
✉ Email this page to a colleague
All Clinical Trials for Lescol Xl
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00421005 ↗ | Fluvastatin After Heart Transplantation | Unknown status | University of Bologna | Phase 4 | 2004-11-01 | Statin therapy is a treatment with a proven positive impact on survival after heart transplantation. However, it is unclear whether the beneficial effect of this class of drugs depends solely on their LDL-lowering properties or on anti-inflammatory and immuno-modulatory properties. Thus, this study was designed to compare safety and efficacy of two different strategies: 1. high fixed statin dose vs. 2. low starting dose with LDL-driven doses adjustments. |
NCT00487318 ↗ | Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin | Completed | US Department of Veterans Affairs | Phase 2 | 2007-06-01 | Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert. |
NCT00487318 ↗ | Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin | Completed | VA Office of Research and Development | Phase 2 | 2007-06-01 | Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert. |
NCT00487318 ↗ | Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin | Completed | Bader, Ted, M.D. | Phase 2 | 2007-06-01 | Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration. It is a randomized control format including genotypes 1 and 3. There will also be pilot arms for HCV carriers who present for screening already on a statin, who will be allowed to stay on their current statin or switched to another statin. In all ways, standard therapy as noted on pegylated interferon and ribavirin will be given per FDA package insert. |
NCT00532311 ↗ | Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia | Terminated | Takeda | Phase 3 | 2007-07-01 | The purpose of the study is to determine the efficacy of lapaquistat acetate, once daily (QD), taken with statins on cholesterol levels in subjects with hypercholesterolemia |
NCT00814723 ↗ | Fluvastatin 80 mg Ret. vs Combination With Ezetimibe 10 mg in Patients With High Cardiovascular Risk | Completed | Medical University of Graz | Phase 4 | 2005-09-01 | Patients with coronary heart disease (CHD) or CHD equivalent (e. g. diabetes mellitus) often have abnormalities in lipids (hypercholesterolemia). Besides, hypercholesterolemia is an evident risk factor for atherosclerosis. Hitherto, there are only few studies of patients with primary hypercholesterolemia where the combination therapy with statins (HMG-Co-reductase inhibitors) and ezetimib was investigated. This combination therapy should be more effective in reducing low density lipoprotein cholesterol (LDL-C) and total cholesterol levels compared to monotherapy. |
NCT00821574 ↗ | Reducing the Overall Risk Level in Patients Suffering From Metabolic Syndrome | Completed | Novartis | Phase 4 | 2005-07-01 | This study will evaluate the efficacy of a multi factorial preventive scheme of action (including fluvastatin and valsartan) to reduce the overall risk level in patients with metabolic syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lescol Xl
Condition Name
Clinical Trial Locations for Lescol Xl
Trials by Country
Clinical Trial Progress for Lescol Xl
Clinical Trial Phase
Clinical Trial Sponsors for Lescol Xl
Sponsor Name